Saredutant

From WikiMD.org
Jump to navigation Jump to search

Saredutant

Saredutant (pronunciation: sah-reh-doo-tant) is a non-peptide antagonist of the neurokinin 2 receptor (NK2 receptor). It was developed by Sanofi-Aventis for the treatment of anxiety disorders and depression.

Etymology

The name "Saredutant" is a portmanteau of the words "Sanofi-Aventis", the pharmaceutical company that developed the drug, and "antagonist", referring to its function as a receptor antagonist.

Function

Saredutant works by blocking the NK2 receptor, a type of G protein-coupled receptor found in the nervous system. This receptor is involved in the transmission of pain signals and the regulation of mood and anxiety. By blocking this receptor, Saredutant can potentially alleviate symptoms of anxiety and depression.

Clinical Trials

Saredutant has undergone Phase II and III clinical trials for the treatment of anxiety and depression. However, as of 2020, it has not been approved for use by any major regulatory authority.

Related Terms

  • Neurokinin 2 receptor: A type of G protein-coupled receptor found in the nervous system. Saredutant is an antagonist of this receptor.
  • Sanofi-Aventis: A multinational pharmaceutical company that developed Saredutant.
  • Anxiety disorders: A group of mental disorders characterized by significant feelings of anxiety and fear.
  • Depression: A mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing significant impairment in daily life.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski